News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
328,664 Results
Type
Article (19665)
Company Profile (139)
Press Release (308860)
Section
Business (105209)
Career Advice (872)
Deals (18498)
Drug Delivery (93)
Drug Development (50666)
Employer Resources (79)
FDA (7638)
Job Trends (7719)
News (185557)
Policy (17300)
Tag
Academia (727)
Alliances (27738)
Alzheimer's disease (577)
Approvals (7620)
Artificial intelligence (86)
Bankruptcy (170)
Best Places to Work (5528)
Biosimilars (71)
Breast cancer (80)
Cancer (690)
Cardiovascular disease (68)
Career advice (707)
Cell therapy (105)
Clinical research (41998)
Collaboration (268)
Compensation (88)
COVID-19 (1075)
C-suite (67)
Data (762)
Diabetes (105)
Diagnostics (1722)
Drug pricing (97)
Earnings (38306)
Employer resources (73)
Events (47800)
Executive appointments (252)
FDA (7965)
Funding (189)
Gene therapy (93)
GLP-1 (507)
Government (1802)
Healthcare (5865)
Infectious disease (1128)
Inflammatory bowel disease (72)
Interviews (115)
IPO (7309)
Job creations (2431)
Job search strategy (646)
Layoffs (255)
Legal (4081)
Lung cancer (107)
Lymphoma (65)
Manufacturing (147)
Medical device (1951)
Medtech (1954)
Mergers & acquisitions (11271)
Metabolic disorders (365)
Neuroscience (771)
NextGen Class of 2024 (2347)
Non-profit (903)
Northern California (753)
Obesity (234)
Opinion (177)
Patents (83)
People (33003)
Pharmaceutical (78)
Phase I (13108)
Phase II (17773)
Phase III (14301)
Pipeline (320)
Policy (73)
Postmarket research (1617)
Preclinical (4592)
Radiopharmaceuticals (156)
Rare diseases (165)
Real estate (3164)
Regulatory (12204)
Research institute (816)
Resumes & cover letters (138)
Southern California (695)
Startups (2005)
United States (6890)
Vaccines (216)
Weight loss (198)
Date
Last 7 days (325)
Last 30 days (1183)
Last 365 days (17645)
2024 (17571)
2023 (19648)
2022 (25867)
2021 (26639)
2020 (24872)
2019 (20059)
2018 (15588)
2017 (17254)
2016 (16202)
2015 (18801)
2014 (14787)
2013 (12552)
2012 (13482)
2011 (13817)
2010 (12738)
Location
Africa (406)
Asia (24548)
Australia (3159)
California (1710)
Canada (833)
China (183)
Colorado (72)
Connecticut (71)
Europe (50648)
Florida (252)
Illinois (174)
Indiana (127)
Japan (66)
Maryland (251)
Massachusetts (1428)
Minnesota (99)
New Jersey (673)
New York (492)
North Carolina (377)
Northern California (753)
Ohio (64)
Pennsylvania (405)
South America (603)
Southern California (695)
Texas (232)
Washington State (157)
328,664 Results for "biohaven pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Neurodegenerative disease
Biohaven Drug Misses in Phase III for SMA, Will Be Tested in Obesity
While taldefgrobep alfa failed to show improved motor function in spinal muscular atrophy, treated patients saw a marked reduction in body fat. Biohaven plans to launch a Phase II trial in obesity by the end of the year.
November 25, 2024
·
2 min read
·
Tristan Manalac
Neurodegenerative disease
Biohaven Sets Stage for Comeback With Pivotal Study Results in Spinocerebellar Ataxia
The FDA previously refused to review Biohaven’s candidate in the indication due to a failed late-stage trial. However, the company is now planning to file an NDA in the fourth quarter of 2024.
September 24, 2024
·
2 min read
·
Tristan Manalac
Drug Development
Biohaven’s Phase I Data for Lead Protein Degrader Disappoints Investors
Despite Biohaven’s bispecific protein degrader cutting autoantibody IgG levels by up to 37% in an early-stage study, investors saw it as “below the high bar” of 60%, according to William Blair analysts.
May 30, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments
November 12, 2024
·
16 min read
Business
Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments
Biohaven Ltd. reported financial results for the first quarter ended March 31, 2024, and provided a review of recent accomplishments and anticipated upcoming developments.
May 9, 2024
·
16 min read
Pharm Country
Biohaven Announces Proposed Public Offering of Common Shares - April 17, 2024
Biohaven Ltd. announced that it has commenced an underwritten public offering of $200 million of its common shares.
April 17, 2024
·
3 min read
Drug Development
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
Biohaven Ltd. announced the first patient has been dosed in a first-in-human Phase 1/2 study of BHV-1510, a highly differentiated Trophoblast Cell Surface Antigen-2 (Trop-2) directed Antibody Drug Conjugate (ADC), and the lead ADC program to advance into clinical trials in Biohaven’s growing oncology pipeline.
May 29, 2024
·
6 min read
Pharm Country
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
Biohaven Ltd. announced the pricing of its underwritten public offering of 5,609,757 of its common shares at a price to the public of $41.00 per share.
April 18, 2024
·
3 min read
Press Releases
Biohaven Announces Pricing of $250 Million Public Offering of Common Shares
October 1, 2024
·
3 min read
Business
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a review of recent accomplishments and anticipated upcoming developments.
February 29, 2024
·
28 min read
1 of 32,867
Next
